hit counter
Ascendis Pharma A/S (ASND) Stock News Sentiment & Price - Sentifly
ASND - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Ascendis Pharma A/S (ASND)

Denmark
Biotechnology
NASDAQ
ASND Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ASND Latest news
Seeking Alpha
Neutral
Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q3 2021 Results - Earnings Call Transcript
2021-11-11 00:13

Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q3 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
2021-11-10 16:01

– SKYTROFA ® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Third Quarter 2021 Financial Results and Business Update Conference Call on November 10
2021-11-03 08:00

COPENHAGEN, Denmark, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced that the Company will hold a conference call and live webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2021 financial results and provide a business update.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces U.S. Commercial Launch of SKYTROFA® (Lonapegsomatropin-tcgd), the First and Only FDA Approved Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
2021-10-15 08:00

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg (25.4 lb) and have growth failure due to inadequate secretion of endogenous growth hormone (GH). SKYTROFA (lonapegsomatropin-tcgd) is available by prescription and distributed through a network of specialty pharmacies across the United States.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Share Repurchase Program
2021-09-29 16:01

COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that its Board of Directors has authorized the Company to repurchase up to $25 million of the Company's American Depositary Shares (ADS) (the Share Repurchase Program), each of which represents one ordinary share of Ascendis Pharma A/S. The program will be executed under Rules 10b-18 and 10b5-1 of the U.S. securities regulations.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
2021-09-22 16:27

– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –

Seeking Alpha
Positive
Ascendis Pharma: A Promising Platform And A Rich Valuation
2021-09-10 09:38

The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum of the parts figure based on the current pipeline assets.

Zacks Investment Research
Positive
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
2021-09-08 12:30

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Announces Upcoming Investor Presentations
2021-09-07 17:09

COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that the company will participate in two upcoming investor conferences. Company executives will provide a business overview and update on the company's programs.

GlobeNewsWire
Neutral
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 ?/? Clinical Program
2021-09-07 16:59

– TransCon IL-2 ?/?  is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2R?/?  with low C max –

Loading more news...